Lupin's New Jersey manufacturing facility received EIR FDA certification

Mumbai: Lupin Limited today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Somerset, NJ manufacturing facility, after the inspection of the facility in March 2022. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

"This is a significant milestone for our Somerset site, and an important step in our journey to rebuild our reputation as best in class in quality and compliance. We are committed to manufacturing and supplying products of the highest quality for the patients we serve, "said Vinita Gupta, CEO, Lupin.

Commenting on the development, Nilesh Gupta, Managing Director, Lupin said, "With this positive development, we now look forward to building a sustainable business from our Somerset facility, and carrying this momentum to positive outcomes for our other sites."